S-Biomedic, a pioneer in patented human microbiome skin applications, announces the successful completion of their second Series A financing round. The second closing welcomed a new investor, DSM Venturing and was also supported by existing […]
Viome announces it has entered into an agreement with Campbell Soup Company (NYSE:CPB) to acquire Habit, a leading personalized nutrition company that takes the guesswork out of eating right. Now operating as one, the two […]
Archer Daniels Midland Company (NYSE: ADM) announced today that it has successfully completed its €1.544 billion acquisition of Neovia, creating a global leader in value-added products and solutions for both production and companion animals. “The […]
Microbiome discovery platform company Eagle Genomics announces funding of $3.5M led by the Environmental Technologies Fund (ETF Partners), a European growth fund specialising in promoting sustainability through innovation. The raise will accelerate the development of […]
Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together specialist expertise […]
Bioharmony Therapeutics, Inc. (“Bioharmony”), a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced today that it has entered into a Collaborative Research and Licensing Agreement with Boehringer […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff […]
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close […]
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40 […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that it has raised $27 million in a Series C financing with […]
Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients […]